Efforts to Prove Drug-Eluting Stent Safety Continue

In its latest study to offer insight into the safety of drug-eluting stents, Boston Scientific revealed favorable findings about its Taxus device at a cardiovascular conference yesterday. Partially funded by Boston Scientific, the study looked at the safety of stents in heart attack patients and found that, after one year, there was comparable efficacy between drug-eluting and bare metal stents.

October 16, 2008

1 Min Read
Efforts to Prove Drug-Eluting Stent Safety Continue

It also found a "statistically significant 41% reduction in revascularization in the TAXUS Express group," according to a Boston Scientific release. Principal investigator Gregg Stone, MD, said the study will have a major impact on decisions made involving drug-eluting and bare metal stents in high risk patients, along with removing the uncertainty related to the safety and efficacy of drug-eluting stents in such patients. The patients in the trial will be followed for five years.

Sign up for the QMED & MD+DI Daily newsletter.

You May Also Like